These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 528399)

  • 21. Adenosine deaminase inhibitors: differential effects on multiple forms of adenosine deaminase.
    Constine J; Glazer RI; Johns DG
    Biochem Biophys Res Commun; 1978 Nov; 85(1):198-202. PubMed ID: 570397
    [No Abstract]   [Full Text] [Related]  

  • 22. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
    Smith CM; Henderson JF
    Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenosine deaminase and adenylate deaminase: comparative kinetic studies with transition state and ground state analogue inhibitors.
    Frieden C; Kurz LC; Gilbert HR
    Biochemistry; 1980 Nov; 19(23):5303-9. PubMed ID: 7448172
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of pentostatin (2'deoxycoformycin), an inhibitor of adenosine deaminase, on type II collagen-induced arthritis in rats.
    Gilbertsen RB
    J Immunopharmacol; 1985; 7(3):325-41. PubMed ID: 3877119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transition-state stabilization by adenosine deaminase: structural studies of its inhibitory complex with deoxycoformycin.
    Frick L; Wolfenden R; Smal E; Baker DC
    Biochemistry; 1986 Apr; 25(7):1616-21. PubMed ID: 3486673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 28. Tight-binding inhibitors--III. A new approach for the determination of competition between tight-binding inhibitors and substrates--inhibition of adenosine deaminase by coformycin.
    Cha S
    Biochem Pharmacol; 1976 Dec; 25(24):2695-702. PubMed ID: 1008893
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics of 2'-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat.
    Geiger JD; Lewis JL; MacIntyre CJ; Nagy JI
    Neuropharmacology; 1987 Sep; 26(9):1383-7. PubMed ID: 3499581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 32. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of maturation of human precursor lymphocytes by coformycin, an inhibitor of the enzyme adenosine deaminase.
    Ballet JJ; Insel R; Merler E; Rosen FS
    J Exp Med; 1976 May; 143(5):1271-6. PubMed ID: 1262787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of adenosine deaminase in some experimental animal tumours and the possible therapeutic effect of the ADA inhibitor 2-deoxy-coformycin.
    Hall JG; Gyure L; Peppard J; Orlans E
    Br J Cancer; 1979 Nov; 40(5):750-4. PubMed ID: 508578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of adenosine deaminase.
    Agarwal RP
    Pharmacol Ther; 1982; 17(3):399-429. PubMed ID: 6187032
    [No Abstract]   [Full Text] [Related]  

  • 37. Deoxy-ATP accumulation in adenosine deaminase-inhibited human B and T lymphocytes.
    Gruber HE; Cohen AH; Firestein GS; Redelman D; Bluestein HG
    Adv Exp Med Biol; 1986; 195 Pt A():503-7. PubMed ID: 3487921
    [No Abstract]   [Full Text] [Related]  

  • 38. In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin.
    Smyth JF; Young RC; Young DM
    Cancer Chemother Pharmacol; 1978; 1(1):49-51. PubMed ID: 750104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
    [No Abstract]   [Full Text] [Related]  

  • 40. Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia.
    Mitchell BS; Sidi Y; Hershfield M; Koller CA
    Ann N Y Acad Sci; 1985; 451():129-37. PubMed ID: 3878114
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.